DataVXACS Materials LettersPaper
journal article·2024-07-01

2′-Fluorinated Antisense Oligonucleotide-Mediated Drug Self-Assembly Strategy for the Efficient Synergistic Anti-Tumor Therapy

Zhangcheng Fu, Yuhong Lin, Han Xiao, Haihui Wang, Yongfei Liu, Yurong Gong, Liannishang Li, Xiaoyong Chen, Chunsen Li, Chenyu Ding, Chunhua Lu

ACS Materials Letters· Volume 6· Issue 7
Publisher page
Source abstract

Abstract

Nanodrugs composed of pure pharmacologically active molecules have been extensively researched as emerging nanomedicines for cancer treatment. However, traditional preparation approaches are generally limited by low production rates, complicated preparation processes, and high production costs. Here, we presented a simple strategy for constructing drug-based nanoparticles (2′F-ASO/CPT NPs) consisting of pure therapeutic molecules by utilizing 2′-fluoro-substituted antisense oligonucleotide (2′F-ASO)-mediated self-assembly with the anticancer agent camptothecin (CPT). The 2′F-substitution could enhance the intermolecular interactions between DNA and CPT through electrostatic and dispersion interactions. The resulting 2′F-ASO/CPT NPs had a high drug loading capacity and improved drug stability. 2′F-ASO/CPT NPs could specifically respond to P-glycoprotein (P-gp) mRNA and inhibit the expression of P-gp, protecting CPT from P-gp-mediated drug efflux. Therefore, the synergistic anticancer effect caused by 2′F-ASO/CPT NPs could be successfully achieved. This work presented a new 2′F-ASO-mediated drug self-assembly strategy for carrier-free chemotherapy–gene therapy with the potential to enhance cancer treatment efficacy.
Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery, Fujian Institute of Brain Disorders and Brain Science, and Fujian Clinical Research Center for Neurological Diseases, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350005, P. R. China

Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350207, P. R. China

MOE Key Laboratory for Analytical Science of Food Safety and Biology, Fujian Provincial Key Laboratory of Analysis and Detection Technology for Food Safety, Fuzhou University, Fuzhou, Fujian 350116, P. R. China

Zhejiang Provincial Key Laboratory of Plant Evolutionary Ecology and Conservation, Taizhou Key Laboratory of Biomedicine and Advanced Dosage Forms, School of Life Sciences, Taizhou University, Taizhou, Zhejiang 318000, P. R. China

State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian 350002, P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (42)

Show source-provided references
1. 10.1002/anie.20210440810.1002/anie.202104408 ↗
2. 10.1039/C5CS00645G10.1039/C5CS00645G ↗
3. 10.1002/adma.20200041610.1002/adma.202000416 ↗
4. 10.1021/acsnano.7b0821910.1021/acsnano.7b08219 ↗
5. 10.1002/adfm.20190172210.1002/adfm.201901722 ↗
6. 10.1002/adfm.20170545110.1002/adfm.201705451 ↗
7. 10.1021/acs.chemmater.8b0093410.1021/acs.chemmater.8b00934 ↗
8. 10.1038/nmat377610.1038/nmat3776 ↗
9. 10.1016/j.bioactmat.2021.05.03810.1016/j.bioactmat.2021.05.038 ↗
10. 10.1002/anie.20080258510.1002/anie.200802585 ↗
11. 10.1021/ja207150n10.1021/ja207150n ↗
12. 10.1002/anie.20210839310.1002/anie.202108393 ↗
13. 10.1021/acsami.1c2089810.1021/acsami.1c20898 ↗
14. 10.1002/adfm.20220092410.1002/adfm.202200924 ↗
15. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
16. 10.1016/j.jconrel.2017.03.10410.1016/j.jconrel.2017.03.104 ↗
17. 10.1002/adma.20220389010.1002/adma.202203890 ↗
18. 10.1002/advs.20180015510.1002/advs.201800155 ↗
19. 10.1021/acsnano.8b0968110.1021/acsnano.8b09681 ↗
20. 10.1021/jacs.1c0555110.1021/jacs.1c05551 ↗
21. 10.1016/j.biomaterials.2019.11941210.1016/j.biomaterials.2019.119412 ↗
22. 10.1016/j.biomaterials.2017.08.02610.1016/j.biomaterials.2017.08.026 ↗
23. 10.1039/C7CS00219J10.1039/C7CS00219J ↗
24. 10.1002/smll.20160032510.1002/smll.201600325 ↗
25. 10.1021/nl500618u10.1021/nl500618u ↗
26. 10.7150/thno.1185210.7150/thno.11852 ↗
27. 10.1002/smll.20110043610.1002/smll.201100436 ↗
28. 10.1016/j.ccr.2023.21534410.1016/j.ccr.2023.215344 ↗
29. 10.1016/j.biomaterials.2016.10.01610.1016/j.biomaterials.2016.10.016 ↗
30. 10.1021/acsnano.2c1223310.1021/acsnano.2c12233 ↗
31. 10.1016/j.nantod.2023.10176610.1016/j.nantod.2023.101766 ↗
32. 10.1016/j.cej.2023.14441110.1016/j.cej.2023.144411 ↗
33. 10.1016/j.matdes.2023.11245710.1016/j.matdes.2023.112457 ↗
34. 10.1016/j.jconrel.2024.04.00710.1016/j.jconrel.2024.04.007 ↗
35. 10.1002/adma.20220301910.1002/adma.202203019 ↗
36. 10.1002/anie.20140929310.1002/anie.201409293 ↗
37. 10.1002/med.2166910.1002/med.21669 ↗
38. 10.1038/nrc156610.1038/nrc1566 ↗
39. 10.1021/nl801736q10.1021/nl801736q ↗
40. 10.1021/nl503598u10.1021/nl503598u ↗
41. 10.1002/anie.20201280110.1002/anie.202012801 ↗
42. 10.1002/adma.20200001310.1002/adma.202000013 ↗